title: Antiplatelet therapy in patients receiving aortic bioprostheses: a report of clinical and instrumental safety.
abstract: OBJECTIVE
  The main advantage of bioprostheses, avoidance of anticoagulant therapy, is compromised during the early postoperative period; in fact, warfarin is often administered during the first 3 postoperative months.
  
  
  METHODS
  We analyzed 250 patients undergoing tissue aortic valve replacement between January 2002 and December 2005. The patients received either aspirin (group 1) or oral anticoagulation (group 2) during the first 3 months. In a subgroup of these patients, we investigated the possible presence of clinically silent microembolization by means of transcranial Doppler for microembolic signal detection.
  
  
  RESULTS
  Thirty-day mortality was 0%. No major neurologic events occurred. Two episodes of bleeding were observed in both groups. Follow-up time was 24 +/- 14 months. Overall late mortality rate was 0.8% in group 1 versus 12% (mainly cancer related) in group 2. In group 2, 2 deaths were due to major ischemic neurologic events; overall, 3 major neurologic episodes occurred (international normalized ratio was within therapeutic range). There were no neurologic events in group 1 (P = .12). Stroke-free survival did not reach statistical significance between the 2 groups. Transcranial Doppler was performed after a mean interval of 55 +/- 19 days, with no detection of microembolic signals in patients receiving either aspirin or warfarin. There were no episodes of bleeding or neurologic events.
  
  
  CONCLUSIONS
  Aspirin therapy appears to be the appropriate response to both cardiac surgeons' and patients' needs in the early postoperative course after aortic valve replacement with tissue valves, demonstrating adequate antithromboembolic efficacy with no added risk for bleeding as well as ease of administration.
authors.affiliation: Department of Cardiologic, Thoracic and Vascular Sciences, Division of Cardiac Surgery, Padua University Medical School, Padova, Italy.
authors.forename: Francesca
authors.initials: F
authors.lastname: di Marco
authors.forename: Silvia
authors.initials: S
authors.lastname: Grendene
authors.forename: Giuseppe
authors.initials: G
authors.lastname: Feltrin
authors.forename: Dino
authors.initials: D
authors.lastname: Meneghetti
authors.forename: Gino
authors.initials: G
authors.lastname: Gerosa
mesh_terms: D000368:Aged; D000704:Analysis of Variance; D000925:Anticoagulants / Q000008:administration & dosage*; D001021:Aortic Valve / Q000601:surgery*; D001705:Bioprosthesis; D016009:Chi-Square Distribution; D005260:Female; D006350:Heart Valve Prosthesis; D019918:Heart Valve Prosthesis Implantation / Q000379:methods; D006493:Heparin / Q000008:administration & dosage*; D006801:Humans; D020766:Intracranial Embolism / Q000000981:diagnostic imaging / Q000517:prevention & control*; D008297:Male; D016019:Survival Analysis; D016896:Treatment Outcome; D017585:Ultrasonography, Doppler, Transcranial; D014859:Warfarin / Q000008:administration & dosage*
chemical_list: D000925:Anticoagulants; D014859:Warfarin; D006493:Heparin